|
Mr. Lapalme has served as a director of BioMarin since January 2004. From 1995 until his retirement in 2003, he served as the president and chief executive officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry including chief executive officer and chairman of the board of Rhône-Poulenc Pharmaceuticals, Inc. in Canada, and senior vice president and general manager of North America Ethicals, a division of Rhône- Poulenc Rorer, Inc. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada where he played a leading role in reinstituting patent protection for pharmaceuticals. Mr. Lapalme currently serves as non-executive chairman of the board of Diagnocure, a biotechnology company, and as director of First Horizon Pharmaceuticals. He is a board member of EXIMIAS Pharmaceutical Corporation and International Wex Technologies. Mr. Lapalme studied at the University of Western Ontario and INSEAD France. | 